Angela Schwab, founder and CEO of Trialynx, discusses the current state of AI in the pharmaceutical industry and why it’s ...

Alnylam Pharmaceuticals has announced a $250 million investment to expand its manufacturing facility in Massachusetts. The ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

In the absence of clear regulatory standards, oversight is increasingly being defined through audits, investigations, and enforcement actions by federal regulators and state medical boards rather than ...

Humans also create value through ethical restraint, the ability to recognize when not to cut corners, when to delay, and when to prioritize patient safety or scientific rigor over speed. That human ...